Biogen Gets FDA Nod For Controversial Alzheimer's Drug; First Treatment Approval For The Disease In 18 Years
Biogen Shares Jump After FDA Delays Aducanumab Decision By 3 Months
Analysts Predict Volatility In Biogen Shares Until March 2021
Biogen's Aducanumab Fails To Win FDA Panel Backing
Biogen Surges Higher On Favorable FDA Briefing Doc For Alzheimer's Candidate